Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers Squibb (BMY) is trending on Zacks.com, with shares down 4.7% over the past month versus a 7.4% gain for the S&P 500. While the current fiscal year earnings are projected to increase significantly (499.1%), revenue and earnings are expected to decline in the coming quarters, with projected revenue declines of 4.1% and 7.5% for the current and next fiscal years, respectively, and a projected 11.8% decrease in earnings for the next fiscal year; the stock currently holds a Zacks Rank #3, suggesting market-average performance in the near term, and is considered undervalued relative to its peers.

Analysis

Bristol Myers Squibb (BMY) has recently underperformed, with its shares declining 4.7% over the past month, contrasting with the S&P 500's 7.4% gain and its Medical - Biomedical and Genetics industry peer group's 0.3% rise. Analyst expectations for the current quarter point to an earnings per share (EPS) of $1.67, a significant 19.3% year-over-year decrease, with the consensus estimate having seen a minor -0.3% revision in the last 30 days. While the current fiscal year's consensus EPS of $6.89 indicates a substantial 499.1% year-over-year increase (largely reflecting a recovery from a prior year that included periods of significantly negative earnings, such as the -$4.40 EPS reported in the corresponding quarter a year ago), this outlook is followed by a projected 11.8% EPS decline to $6.08 for the next fiscal year, an estimate that has edged up +0.3% recently. Revenue projections also signal challenges, with an anticipated 7.2% year-over-year decline to $11.32 billion for the current quarter, and further estimated decreases of 4.1% and 7.5% for the current and next fiscal years, respectively. Despite these forward-looking headwinds, BMY's most recent reported quarter demonstrated strength, with revenues of $11.2 billion (-5.6% YoY) surpassing estimates by 4.38%, and an EPS of $1.80 beating consensus by 19.21%; the company has consistently exceeded both EPS and revenue estimates over the trailing four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market, and notably receives an 'A' grade for Value from Zacks, indicating it may be trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should carefully weigh BMY's 'A' grade valuation, indicating a potential discount to peers, and its consistent history of earnings beats against significant projected year-over-year declines in both revenue and earnings for the upcoming quarters and the next fiscal year.
• Monitor upcoming quarterly results and management guidance closely for any deviations from the negative consensus estimates, particularly regarding revenue trajectory and the drivers for the forecasted earnings decrease in the next fiscal year, as these will be critical in assessing the appropriateness of the current valuation.
• The Zacks Rank #3 (Hold) suggests that while the stock may be attractively valued, a cautious approach of holding existing positions or waiting for clearer signals of a turnaround in fundamental growth prospects may be prudent before initiating new long positions, given the anticipated near-term operational headwinds.